Elisabetta Babetto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisabetta Babetto has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Bogdan Beirowski
Department of Neurology, The Neuroscience Research Institute, College of Medicine, The Ohio State University Wexner Medical Center
8 shared publications - Keit Men Wong
Division of Pharmaceutical Sciences University of Wyoming Laramie Wyoming USA
3 shared publications Derek Thomson
Euan MacDonald Centre for MND Research, Edinburgh EH8 9JZ, United Kingdom
1 shared publicationHaoran Huang
Department of Neurology, The Neuroscience Research Institute, College of Medicine, The Ohio State University Wexner Medical Center
1 shared publication- Haoran Huang
Department of Neurology, The Neuroscience Research Institute, College of Medicine, The Ohio State University Wexner Medical Center
1 shared publication - Jeffrey Milbrandt
Department of Genetics, Washington University School of Medicine, St. Louis, USA
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Death receptor 6 does not regulate axon degeneration and Schwann cell injury responses during Wallerian degeneration
Axon degeneration (AxD), accompanied by glial remodeling, is a pathological hallmark of many neurodegenerative diseases, leading to the disruption of neuronal connectivity. Understanding the mechanisms in neurons and glia that regulate AxD is essential for developing therapeutic strategies to prevent or mitigate axon loss. Wallerian degeneration (WD) is a well-established model to study the mechanisms of nerve injury-induced AxD, glial responses, and axon-glia interactions. We recently showed that Schwann cells (SCs), the axon-associated glia of the peripheral nervous system, exert protective effects on axons through their rapid metabolic injury response. Enhancing this SC response promotes axon protection during WD. A prior study reported that eliminating the orphan tumor necrosis factor receptor DR6 (death receptor 6, encoded by Tnfrsf21 ) strongly delays AxD and alters SC injury responses during WD, suggesting a possible intersection with our findings. Here, we rigorously revisit the role of DR6 in WD using two independent DR6 knockout mouse lines including the same model used in the previous study. Surprisingly, in contrast to the earlier report, we observed no impact of DR6 deletion on AxD kinetics or SC injury responses across a range of WD assays. Moreover, injured axons in primary neuronal cultures lacking DR6 degenerated at a similar rate as wild-type axons. We conclude that DR6 is dispensable for the regulation of AxD and glial nerve injury responses during WD. Our data argue that any therapeutic benefit from DR6 suppression in neurodegeneration models occurs through mechanisms independent of WD.
- 27 March 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessDeath receptor 6 does not regulate axon degeneration and Schwann cell injury responses during Wallerian degeneration
Axon degeneration (AxD), accompanied by glial remodeling, is a pathological hallmark of many neurodegenerative diseases, leading to the disruption of neuronal connectivity. Understanding the mechanisms in neurons and glia that regulate AxD is essential for developing therapeutic strategies to prevent or mitigate axon loss. Wallerian degeneration (WD) is a well-established model to study the mechanisms of nerve injury-induced AxD, glial responses, and axon-glia interactions. We recently showed that Schwann cells (SCs), the axon-associated glia of the peripheral nervous system, exert protective effects on axons through their rapid metabolic injury response. Enhancing this SC response promotes axon protection during WD. A prior study reported that eliminating the orphan tumor necrosis factor receptor DR6 (death receptor 6, encoded by Tnfrsf21 ) strongly delays AxD and alters SC injury responses during WD, suggesting a possible intersection with our findings. Here, we rigorously revisit the role of DR6 in WD using two independent DR6 knockout mouse lines including the same model used in the previous study. Surprisingly, in contrast to the earlier report, we observed no impact of DR6 deletion on AxD kinetics or SC injury responses across a range of WD assays. Moreover, injured axons in primary neuronal cultures lacking DR6 degenerated at a similar rate as wild-type axons. We conclude that DR6 is dispensable for the regulation of AxD and glial nerve injury responses during WD. Our data argue that any therapeutic benefit from DR6 suppression in neurodegeneration models occurs through mechanisms independent of WD.
- Open Access
- 20 February 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Death receptor 6 does not regulate axon degeneration and Schwann cell injury responses during Wallerian degeneration
Axon degeneration (AxD), accompanied by glial remodeling, is a pathological hallmark of many neurodegenerative diseases, leading to the disruption of neuronal connectivity [1–3]. Understanding the mechanisms in neurons and glia that regulate AxD is essential for developing therapeutic strategies to prevent or mitigate axon loss. Wallerian degeneration (WD) is a well-established model to study the mechanisms of nerve injury-induced AxD, glial responses, and axon-glia interactions. We recently showed that Schwann cells (SCs), the axon-associated glia of the peripheral nervous system, exert protective effects on axons through their rapid metabolic injury response [4]. Enhancing this SC response promotes axon protection during WD [4]. A prior study reported that eliminating the orphan tumor necrosis factor receptor DR6 (death receptor 6, Tnfrsf21) strongly delays AxD and alters SC injury responses during WD [5], suggesting a possible intersection with our findings. Here, we rigorously revisit the role of DR6 in WD using two independent DR6 knockout mouse lines including the same model used in the previous study. Surprisingly, in striking contrast to the earlier report, we observed no impact of DR6 deletion on AxD kinetics or SC injury responses across a range of WD assays. Moreover, injured axons in primary neuronal cultures lacking DR6 degenerated at a similar rate as wild-type axons. We conclude that DR6 is dispensable for the regulation of AxD and glial nerve injury responses during WD. Our data argue that any therapeutic benefit from DR6 suppression in neurodegeneration models occurs through mechanisms independent of WD.
- 20 February 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Open AccessDeath receptor 6 does not regulate axon degeneration and Schwann cell injury responses during Wallerian degeneration
Axon degeneration (AxD), accompanied by glial remodeling, is a pathological hallmark of many neurodegenerative diseases, leading to the disruption of neuronal connectivity [1–3]. Understanding the mechanisms in neurons and glia that regulate AxD is essential for developing therapeutic strategies to prevent or mitigate axon loss. Wallerian degeneration (WD) is a well-established model to study the mechanisms of nerve injury-induced AxD, glial responses, and axon-glia interactions. We recently showed that Schwann cells (SCs), the axon-associated glia of the peripheral nervous system, exert protective effects on axons through their rapid metabolic injury response [4]. Enhancing this SC response promotes axon protection during WD [4]. A prior study reported that eliminating the orphan tumor necrosis factor receptor DR6 (death receptor 6, Tnfrsf21) strongly delays AxD and alters SC injury responses during WD [5], suggesting a possible intersection with our findings. Here, we rigorously revisit the role of DR6 in WD using two independent DR6 knockout mouse lines including the same model used in the previous study. Surprisingly, in striking contrast to the earlier report, we observed no impact of DR6 deletion on AxD kinetics or SC injury responses across a range of WD assays. Moreover, injured axons in primary neuronal cultures lacking DR6 degenerated at a similar rate as wild-type axons. We conclude that DR6 is dispensable for the regulation of AxD and glial nerve injury responses during WD. Our data argue that any therapeutic benefit from DR6 suppression in neurodegeneration models occurs through mechanisms independent of WD.
- 23 March 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1863 (5) , 148545
Of axons that struggle to make ends meet: Linking axonal bioenergetic failure to programmed axon degeneration
- 23 March 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1863 (5) , 148545
Of axons that struggle to make ends meet: Linking axonal bioenergetic failure to programmed axon degeneration
- Open Access
- 16 October 2020
- Published by Springer Nature in Nature Neuroscience
- Vol. 24 (1) , 150-153
Publisher Correction: A glycolytic shift in Schwann cells supports injured axons
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 16 October 2020
- Published by Springer Nature in Nature Neuroscience
- Vol. 24 (1) , 150-153
Open AccessPublisher Correction: A glycolytic shift in Schwann cells supports injured axons
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 17 August 2020
- Published by Springer Nature in Nature Neuroscience
- Vol. 23 (10) , 1215-1228
A glycolytic shift in Schwann cells supports injured axons
Axon degeneration is a hallmark of many neurodegenerative disorders. The current assumption is that the decision of injured axons to degenerate is cell-autonomously regulated. Here we show that Schwann cells (SCs), the glia of the peripheral nervous system, protect injured axons by virtue of a dramatic glycolytic upregulation that arises in SCs as an inherent adaptation to axon injury. This glycolytic response, paired with enhanced axon–glia metabolic coupling, supports the survival of axons. The glycolytic shift in SCs is largely driven by the metabolic signaling hub, mammalian target of rapamycin complex 1, and the downstream transcription factors hypoxia-inducible factor 1-alpha and c-Myc, which together promote glycolytic gene expression. The manipulation of glial glycolytic activity through this pathway enabled us to accelerate or delay the degeneration of perturbed axons in acute and subacute rodent axon degeneration models. Thus, we demonstrate a non-cell-autonomous metabolic mechanism that controls the fate of injured axons.
- 17 August 2020
- Published by Springer Nature in Nature Neuroscience
- Vol. 23 (10) , 1215-1228
A glycolytic shift in Schwann cells supports injured axons
Axon degeneration is a hallmark of many neurodegenerative disorders. The current assumption is that the decision of injured axons to degenerate is cell-autonomously regulated. Here we show that Schwann cells (SCs), the glia of the peripheral nervous system, protect injured axons by virtue of a dramatic glycolytic upregulation that arises in SCs as an inherent adaptation to axon injury. This glycolytic response, paired with enhanced axon–glia metabolic coupling, supports the survival of axons. The glycolytic shift in SCs is largely driven by the metabolic signaling hub, mammalian target of rapamycin complex 1, and the downstream transcription factors hypoxia-inducible factor 1-alpha and c-Myc, which together promote glycolytic gene expression. The manipulation of glial glycolytic activity through this pathway enabled us to accelerate or delay the degeneration of perturbed axons in acute and subacute rodent axon degeneration models. Thus, we demonstrate a non-cell-autonomous metabolic mechanism that controls the fate of injured axons.
- 11 June 2020
- Published by Springer Nature
- Vol. 2143, 97-110
A Schwann Cell–Neuron Coculture System to Study Neuron–Glia Interaction During Axon Degeneration
Autonomous mechanisms of axon degeneration are frequently studied in vitro by mechanical axon injury of isolated sensory neurons. This has led to major advances in understanding the molecular pathways governing axon degeneration. However, this approach does not pay attention to potential glial mechanisms for the regulation of axon death. Here, I describe a straightforward protocol to seed purified rat Schwann cells on neuronal cultures in order to study the interaction between axons and these glia during axon degeneration.
- 11 June 2020
- Published by Springer Nature
- Vol. 2143, 97-110
A Schwann Cell–Neuron Coculture System to Study Neuron–Glia Interaction During Axon Degeneration
Autonomous mechanisms of axon degeneration are frequently studied in vitro by mechanical axon injury of isolated sensory neurons. This has led to major advances in understanding the molecular pathways governing axon degeneration. However, this approach does not pay attention to potential glial mechanisms for the regulation of axon death. Here, I describe a straightforward protocol to seed purified rat Schwann cells on neuronal cultures in order to study the interaction between axons and these glia during axon degeneration.
- 8 May 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (21) , E4261-E4270
mTORC1 promotes proliferation of immature Schwann cells and myelin growth of differentiated Schwann cells
Significance: The myelination of axons is essential for neuronal wiring and normal nervous system functions. In the peripheral nervous system, Schwann cells (SCs) form myelin sheaths around axons during nerve development. Such myelination is compromised in a number of diseases. Hence, identification and understanding of the key pathways regulating SC development and myelinogenesis are essential for therapeutic progress. Here we uncover two separate roles of the cellular signaling node mTORC1 (mechanistic target of rapamycin complex 1) for regulating the development of SCs and subsequently the growth of myelin sheaths. Moreover, we demonstrate that defective SCs possess a remarkable plasticity to remyelinate axons via mTORC1. Thus, manipulating mTORC1 activity in diseased SCs could be therapeutically beneficial.
- 8 May 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (21) , E4261-E4270
mTORC1 promotes proliferation of immature Schwann cells and myelin growth of differentiated Schwann cells
Significance: The myelination of axons is essential for neuronal wiring and normal nervous system functions. In the peripheral nervous system, Schwann cells (SCs) form myelin sheaths around axons during nerve development. Such myelination is compromised in a number of diseases. Hence, identification and understanding of the key pathways regulating SC development and myelinogenesis are essential for therapeutic progress. Here we uncover two separate roles of the cellular signaling node mTORC1 (mechanistic target of rapamycin complex 1) for regulating the development of SCs and subsequently the growth of myelin sheaths. Moreover, we demonstrate that defective SCs possess a remarkable plasticity to remyelinate axons via mTORC1. Thus, manipulating mTORC1 activity in diseased SCs could be therapeutically beneficial.
- Open Access
- 1 January 2017
- Published by Medknow in Neural Regeneration Research
- Vol. 12 (4) , 518-524
Axon degeneration: make the Schwann cell great again
Axonal degeneration is a pivotal feature of many neurodegenerative conditions and substantially accounts for neurological morbidity. A widely used experimental model to study the mechanisms of axonal degeneration is Wallerian degeneration (WD), which occurs after acute axonal injury. In the peripheral nervous system (PNS), WD is characterized by swift dismantling and clearance of injured axons with their myelin sheaths. This is a prerequisite for successful axonal regeneration. In the central nervous system (CNS), WD is much slower, which significantly contributes to failed axonal regeneration. Although it is well-documented that Schwann cells (SCs) have a critical role in the regenerative potential of the PNS, to date we have only scarce knowledge as to how SCs 'sense' axonal injury and immediately respond to it. In this regard, it remains unknown as to whether SCs play the role of a passive bystander or an active director during the execution of the highly orchestrated disintegration program of axons. Older reports, together with more recent studies, suggest that SCs mount dynamic injury responses minutes after axonal injury, long before axonal breakdown occurs. The swift SC response to axonal injury could play either a pro-degenerative role, or alternatively a supportive role, to the integrity of distressed axons that have not yet committed to degenerate. Indeed, supporting the latter concept, recent findings in a chronic PNS neurodegeneration model indicate that deactivation of a key molecule promoting SC injury responses exacerbates axonal loss. If this holds true in a broader spectrum of conditions, it may provide the grounds for the development of new glia-centric therapeutic approaches to counteract axonal loss.
- 1 January 2017
- Published by Medknow in Neural Regeneration Research
- Vol. 12 (4) , 518-524
Open AccessAxon degeneration: make the Schwann cell great again
Axonal degeneration is a pivotal feature of many neurodegenerative conditions and substantially accounts for neurological morbidity. A widely used experimental model to study the mechanisms of axonal degeneration is Wallerian degeneration (WD), which occurs after acute axonal injury. In the peripheral nervous system (PNS), WD is characterized by swift dismantling and clearance of injured axons with their myelin sheaths. This is a prerequisite for successful axonal regeneration. In the central nervous system (CNS), WD is much slower, which significantly contributes to failed axonal regeneration. Although it is well-documented that Schwann cells (SCs) have a critical role in the regenerative potential of the PNS, to date we have only scarce knowledge as to how SCs 'sense' axonal injury and immediately respond to it. In this regard, it remains unknown as to whether SCs play the role of a passive bystander or an active director during the execution of the highly orchestrated disintegration program of axons. Older reports, together with more recent studies, suggest that SCs mount dynamic injury responses minutes after axonal injury, long before axonal breakdown occurs. The swift SC response to axonal injury could play either a pro-degenerative role, or alternatively a supportive role, to the integrity of distressed axons that have not yet committed to degenerate. Indeed, supporting the latter concept, recent findings in a chronic PNS neurodegeneration model indicate that deactivation of a key molecule promoting SC injury responses exacerbates axonal loss. If this holds true in a broader spectrum of conditions, it may provide the grounds for the development of new glia-centric therapeutic approaches to counteract axonal loss.
- Open Access
- 6 October 2010
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 30 (40) , 13291-13304
Targeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective PotencyIn Vivo
Axon and synapse degeneration are common components of many neurodegenerative diseases, and their rescue is essential for effective neuroprotection. The chimeric Wallerian degeneration slow protein (WldS) protects axons dose dependently, but its mechanism is still elusive. We recently showed that WldSacts at a non-nuclear location and is present in axons. This and other recent reports support a model in which WldSprotects by extranuclear redistribution of its nuclear NMNAT1 portion. However, it remains unclear whether cytoplasmic NMNAT1 acts locally in axons and synapses or at a non-nuclear site within cell bodies. The potency of axon protection by non-nuclear NMNAT1 relative to WldSalso needs to be establishedin vivo. Because the N-terminal portion of WldS(N70) localized to axons, we hypothesized that it mediates the trafficking of the NMNAT1 portion. To test this, we substituted N70 with an axonal targeting peptide derived from amyloid precursor protein, and fused this to NMNAT1 with disrupted nuclear targeting. In transgenic mice, this transformed NMNAT1 from a molecule unable to inhibit Wallerian degeneration, even at high expression levels, into a protein more potent than WldS, able to preserve injured axons for several weeks at undetectable expression levels. Preventing NMNAT1 axonal delivery abolished its protective effect. Axonally targeted NMNAT1 localized to vesicular structures, colocalizing with extranuclear WldS, and was cotransported at least partially with mitochondria. We conclude that axonal targeting of NMNAT activity is both necessary and sufficient to delay Wallerian degeneration, and that promoting axonal and synaptic delivery greatly enhances the effectiveness.
- 6 October 2010
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 30 (40) , 13291-13304
Open AccessTargeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective PotencyIn Vivo
Axon and synapse degeneration are common components of many neurodegenerative diseases, and their rescue is essential for effective neuroprotection. The chimeric Wallerian degeneration slow protein (WldS) protects axons dose dependently, but its mechanism is still elusive. We recently showed that WldSacts at a non-nuclear location and is present in axons. This and other recent reports support a model in which WldSprotects by extranuclear redistribution of its nuclear NMNAT1 portion. However, it remains unclear whether cytoplasmic NMNAT1 acts locally in axons and synapses or at a non-nuclear site within cell bodies. The potency of axon protection by non-nuclear NMNAT1 relative to WldSalso needs to be establishedin vivo. Because the N-terminal portion of WldS(N70) localized to axons, we hypothesized that it mediates the trafficking of the NMNAT1 portion. To test this, we substituted N70 with an axonal targeting peptide derived from amyloid precursor protein, and fused this to NMNAT1 with disrupted nuclear targeting. In transgenic mice, this transformed NMNAT1 from a molecule unable to inhibit Wallerian degeneration, even at high expression levels, into a protein more potent than WldS, able to preserve injured axons for several weeks at undetectable expression levels. Preventing NMNAT1 axonal delivery abolished its protective effect. Axonally targeted NMNAT1 localized to vesicular structures, colocalizing with extranuclear WldS, and was cotransported at least partially with mitochondria. We conclude that axonal targeting of NMNAT activity is both necessary and sufficient to delay Wallerian degeneration, and that promoting axonal and synaptic delivery greatly enhances the effectiveness.